| Date/App# |
 List of recent Vaccine-related patents |
02/26/15
20150056636 |   Transgenic immunodeficient mouse expressing human sirp-alpha
The present invention provides a transgenic mouse which comprises a deficiency for murine t lymphocytes, b lymphocytes and nk cells, a deficiency for murine mhc class i and mhc class ii molecules, and a functional xenogenic sirpα transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines.
Institut Pasteur |
02/26/15
20150056254 |  Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same
A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use..
Phi Biomed Co., Ltd. |
02/26/15
20150056249 |  Influenza vaccines
The present invention relates to influenza vaccine compositions and vaccination schemes for immunizing against influenza disease, in particular it relates to immunogenic compositions comprising an antigen or a antigenic preparation from a first influenza virus strain and an oil-in-water emulsion adjuvant for use in inducing a immune response against at least one second influenza virus strain wherein said second influenza virus strain is from a different type or from a different subtype than said first influenza virus strain.. .
Glaxosmithkline Biologicals, Sa |
02/26/15
20150056247 |  Sequential and repeated immunization with four or more vector-based hiv gene vaccines
The present invention provides a combined aids vaccine for preventing and/or treating aids, which consists of four or more different vector-based aids vaccines, wherein hiv protein gene comprised in the different aids vaccines may be same. A use method of the vaccine comprises inoculation of one aids vaccine each time, wherein inoculation of each vaccine may be continuously performed twice, and after sequential application of the four or more vector vaccines, repeated sequential application of the vector vaccines may be performed.
Beijing University Of Technology |
02/26/15
20150056244 |  Antigens and vaccines directed against human enteroviruses
The instant invention provides materials and methods for producing immunologically active antigens derived from members of the picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection.
Sentinext Therapeutics Sdn Bhd |
02/26/15
20150056243 |  Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure
A vaccine against the chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.. . |
02/26/15
20150056239 |  Fused antigen vaccines and compositions against streptococcus pneumoniae
Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in streptococcus pneumoniae that contain fusion proteins.
Children's Medical Center Corporation |
|
|
02/26/15
20150056237 |  Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus..
University Of Washington |
02/26/15
20150056236 |  An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of north american prrs virus. The invention also provides vaccines comprising genetically modified north american prrs virus, rna molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules.
Zoetis Llc |
02/26/15
20150056234 |  Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
The present invention relates to novel cd4+ and cd8+ t cell epitopes that are specific for hpv-specific e6 and e7 oncoproteins, to peptides comprising these novel t cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of hpv related diseases. Preferred epitopes are recognized by a t cell that infiltrates a cervical neoplastic lesion or by a t cell from a draining lymph node, and are presented by an hla-dq or hla-dp molecule, or an hla-b..
Academisch Ziekenhuis Leiden H.o.d.n. Lumc |
02/26/15
20150056231 | Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
Recombinant papaya mosaic virus (papmv) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the m2e peptide, fused at a position within a predicted random coil within 13 amino acids of the n-terminus of the coat protein, uses thereof to prepare virus-like particles (vlps), and uses of the vlps in influenza vaccines.. .
Folia Biotech Inc. |
02/26/15
20150056230 | Equine encephalitis virus vaccines and methods of using thereof
Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans. |
02/26/15
20150056228 | Methods and materials for generating t cells
The document provides to methods and materials for generating t cells (e.g., antigen-specific cd4+ t cells). For example, methods and materials for using nested mhc class ii epitopes as vaccines to generate activated cd4+ t cells in vivo or as reagents to generate activated cd4+ t cells ex vivo are provided..
Mayo Foundation For Medical Education And Research |
02/26/15
20150056209 | Peptide mimotopes to oxidation specific epitopes
Provided herein are peptide mimotopes that are useful for generating antibodies and in the preparation of vaccines and diagnostics for treating and diagnosing coronary artery disease.. .
Medizinsche Universitat Wien |
02/26/15
20150056197 | Vaccines against hpv
The present invention relates to therapeutic compounds, such as vaccines against human papillomavirus (hpv) and in particular to dna vaccines against hpv16 or hpv18. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a dna vaccine or used separately.
Vaccibody As |
02/19/15
20150051388 | Immunogen platform
Aspects of the present invention relate to chimeric polypeptides including hcv ns3/4a sequences and t-cell epitopes. Embodiments include nucleic acids encoding the chimeric ns3/4a polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines..
Chrontech Pharma Ab |
02/19/15
20150050319 | Natural saponin-based synthetic immunoadjuvants
The present disclosure encompasses qs-21-based structurally-defined adjuvants to address the need for stronger, safer, and easier-to-access adjuvants. The new compositions can provide tools for addressing long-standing mechanistic questions concerning saponin immune-potentiation through structure-activity-relationship (sar) studies.
The Uab Research Foundation |
02/19/15
20150050318 | Multivalent nanoemulsion vaccines
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response against one or a plurality of pathogens (e.g., vaccinia virus, h5n1 influenza virus, bacillus anthracis, c.
The Regents Of The University Of Michigan |
02/19/15
20150050314 | Conjugates of plasmodium falciparum surface proteins as malaria vaccines
Conjugates of ookinete surface protein pfs25 are provided that are efficacious as vaccines against plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein pvs25 for use as a vaccine against plasmodium vivax are also provided.
The United States Of America As Represented By The Secretary, Department Of Health And Human Service |
02/19/15
20150050310 | Immunogens for hiv vaccination
The present invention relates to novel immunogens based on overlapping peptides (olps) and peptides derived therefrom useful for the prevention and treatment of aids and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including the immunogens..
InstituciÓ Catalana De Recerca I Estudis AvanÇats |
02/19/15
20150050308 | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus.
Amsterdam Institute Of Viral Genomics B.v. |
02/19/15
20150050304 | Cd4+ t survivin epitopes and uses thereof
The present invention concerns cd4+ t survivin epitopes and their vaccines and diagnostic uses.. .
Commissariat A L'energie Atomique |
02/19/15
20150050303 | Compositions and methods for treatment of celiac disease
The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients..
Immusant, Inc. |
02/19/15
20150050215 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.
Axon Neuroscience Se |
02/12/15
20150044256 | Oral vaccine for borrelia
The present invention relates to vaccines for control of borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more borrelia burgdorferi antigens for use as lyme disease vaccines.
Biopeptides, Corporation |
02/12/15
20150044255 | Infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of north american prrs virus. The invention also provides vaccines comprising genetically modified north american prrs virus, rna molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules.
Zoetis Llc |
02/12/15
20150044250 | Vaccines against clostridium difficile comprising recombinant toxins
The present invention relates to recombinant c. Difficile toxin a (tcda) and toxin b (tcdb) and binary toxin a (cdta) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity.
Merck Sharp & Dohme Corp. |
02/12/15
20150044243 | Mucosal immunization to prevent prion infection
Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration.
New York University |
02/12/15
20150044242 | Adjuvant and vaccine compositions
Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin, polymer and one or more additives. The polymer is preferably polyacrylic acid-based.
Advanced Bioadjuvants Llc |
02/12/15
20150044241 | Contraceptive vaccines for mammals
The invention provides a contraceptive vaccine for a female recipient of a target species of mammals including a composition of at least one of a plurality of granulosa cells and a plurality of ovarian stromal cells in combination with an adjuvant; wherein the cells are grown from a tissue sample of the cells obtained from at least one female donor of the target species which is not the same individual as the female recipient. The invention also provides a method of producing the contraceptive vaccine as well as a method of treating a female recipient with the contraceptive vaccine to prevent pregnancy..
Contra Vaccine Limited |
02/12/15
20150044240 | P53 vaccines for the treatment of cancers
The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells.
University Of South Florida |
02/05/15
20150040251 | Sheep nematode vaccine
The present invention is based upon the identification of a number of antigens derived from species of the genus teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate teladorsagia infections/infestations..
Moredun Research Institute |
02/05/15
20150038408 | Polypeptides for treating and/or limiting influenza infection
The present invention provides polypeptides that recognize and are strong binders to influenza a hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention.
University Of Washington Through Its Center For Commercialization |
02/05/15
20150037373 | Method of enhancing the proliferative phase of a primary t cell response
Disclosed is an alkaline extract of shredded pinecones yields a polyphenylpropanoid polysaccharide complex (ppc) that functions as an orally active immune adjuvant. Specifically, the oral ppc boosts the number of antigen-specific memory cd8+ t cells generated in response to a variety of vaccine types (dna, protein, and dendritic cell) and bias the response towards one that is predominately a t helper 1 type.
Tampa Bay Research Institute |
02/05/15
20150037371 | Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite).
The Administrators Of The Tulane Educational Fund |
02/05/15
20150037370 | Diatom-based vaccines
This invention provides diatom-based vaccines.. .
The Regents Of The University Of California |
02/05/15
20150037369 | Methods of transforming a listeria
Site-specific listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source 0 of these elements is a listeriophage.
The Regents Of The University Of California |
02/05/15
20150037368 | Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines
The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) haemophilus influenzae b capsular polysaccharide or oligosaccharide (prp) and (b) at least one non-prp antigen. The invention further relates to kits comprising (i) a first composition comprising a haemophilus influenzae b capsular polysaccharide or oligosaccharide (prp) and a polyanionic polymer, and (ii) a second composition comprising a non-prp antigen adsorbed onto an adjuvant with a zero point charge greater than 8..
Glaxosmithkline Biologicals S.a. |
02/05/15
20150037367 | Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2
Contemplated compositions, devices, and methods are drawn to various antigens from herpes simplex virus type 1 (hsv-1) and herpes simplex virus type 2 (hsv-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.. |
02/05/15
20150037350 | Negative modulator of hedgehog signalling for use in treating th2-mediated diseases
The invention provides means for treating th1- and th2-mediated diseases, such as asthma, allergic dermatitis and th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment.
Ucl Business Plc |
02/05/15
20150037329 | Method of reducing titers of antibodies specific for a therapeutic agent
The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ert) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to dna vaccines, sirna, splice-site switching oligomers (ssos) as well as rna-based nanoparticles (rnps) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods..
Duke University |
01/29/15
20150030634 | Proliferating agent for monocyte, culture medium for proliferating monocyte, producing monocyte, producing dendritic cell, and producing dendritic cell vaccine
The purpose of the present invention is to provide a means for proliferating a monocyte with high efficiency and in a simple manner. The present invention provides a proliferating agent for a monocyte, which consists of at least one component selected from flt-3l, il-3 and ifn-γ and can be used before a treatment for differentiation of a monocyte into a dendritic cell.
Hakushikouseikai Foundation |
01/29/15
20150030630 | Adjuvanted formulations of rabies virus immunogens
The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a tlr agonist (preferably a tlr7 agonist) and an insoluble metal salt (preferably an aluminium salt). The tlr agonist is typically adsorbed to the metal salt.
Novartis Ag |
01/29/15
20150030629 | Methods and compositions for stabilizing dried biological materials
The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt.
En Sport |
01/29/15
20150030627 | Trans-complementing, replication deficient lentiviral vectors and methods for making and using them
The present invention relates to multiple novel approaches for the generation of an immune response in an animal, such as a human, using lentivirus-based vector technology. The invention provides for the ability to mimic the efficacy of a live attenuated (la) vaccine, without exposing the patient to the risk of disease as possible with some la vaccines.
Virxsys.con390 |
01/29/15
20150030621 | Baculovirus-based vaccines
The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., hpv l1), enabling to function as a more efficient dna vaccine..
Kr Biotech Co., Ltd. |
01/29/15
20150030620 | Packaging of immunostimulatory substances into virus-like particles: preparation and use
The invention relates to the finding that virus like particles (vlps) can be loaded with immunostimulatory substances, in particular with dna oligonucleotides containing non-methylated c and g (cpgs). Such cpg-vlps are dramatically more immunogenic than their cpg-free counterparts and induce enhanced b and t cell responses.
Cytos Biotechnology Ag |
01/22/15
20150025600 | Laser-based treatment for malaria
Malaria, caused by the parasite plasmodium, is a devastating disease killing more than 800,000 people a year worldwide. Plasmodium replicates within erythrocytes by digesting hemoglobin, producing haemozoin as a byproduct which accumulates within the parasite. |
01/22/15
20150024037 | Xenoantigen-displaying anti-cancer vaccines and making
Compositions, methods of making, and methods of using, xenoantigen-displaying anticancer vaccines are described. In another broad aspect, there is provided herein a method of synthesizing an alkynefunctionalized composition of claim 1, comprising: deprotecting an ester comprising a fmoc moiety to form a free acid; coupling the free acid of step (a) with an amine; and, removing the fmoc moiety, and coupling the remaining moiety with palmitic acid to yield an alkyne-functionalized composition..
The University Of Toledo |
01/22/15
20150024008 | Methods and compositions involving induced senescent cells for cancer treatment
Disclosed are cancer vaccines comprising senescent cells and methods of using and preparing the vaccines.. .
The University Of Chicago |
01/22/15
20150024004 | Flavivirus vaccines
The invention provides flavivirus vaccines and methods of making and using these vaccines.. .
Sanofi Pasteur Biologics, Llc |
01/22/15
20150024002 | Alphavirus vectors for respiratory pathogen vaccines
Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions..
Novartis Vaccines And Diagnostics, Inc. |
01/22/15
20150024000 | Multivalent vaccine protection from staphylococcus aureus infection
vaccine formulations effective against staphylococcus aureus, including methicillin-resistant staphylococcus aureus (mrsa) are disclosed, as well as methods of using the vaccine formulations in the treatment and prevention of staphylococcus aureus infections in a subject.. .
University Of Maryland, Baltimore |
01/22/15
20150023998 | Stable anthrax vaccine formulations
Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided.
Emergent Biosolutions Inc. |
01/22/15
20150023995 | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide.
Takeda Vaccines, Inc. |
01/22/15
20150023987 | Immunogenic compositions and reagents for preparing
The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.. .
Purdue Research Foundation |
01/15/15
20150017204 | Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, co2, acid ph, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced tnf-α induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbb, that are rendered stress-resistant by a mutation in the zwf gene.
Aviex Technologies Llc |
01/15/15
20150017201 | Novel nicotine dna vaccines
The present invention provides dna-nanostructures comprising and at least one targeting moiety, wherein the at least one targeting moiety is linked to the dna-nanostructure; and wherein the at least one targeting moiety is nicotine or a nicotine analogue. These compounds elicit an immunogenic response in individuals and are useful as vaccines for ameliorating nicotine dependence..
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Ariz |
01/15/15
20150017199 | Cholera toxin chimera and its use as a staph vaccine
The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from s.
Boise State University |
01/15/15
20150017198 | Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersinia pestis as next generation plague vaccines
Techniques from two basic approaches, structure-based immunogen design and phage t4 nanoparticle delivery, are developed to construct new plague vaccines. The nh2-terminal β-strand of f1 of yersinia pestis is transplanted to the cooh-terminus of f1 of yersinia pestis and the nh2-terminus sequence flanking the β-strand of f1 of yersinia pestis is duplicated to eliminate polymerization but to retain the t cell epitopes.
The Catholic University Of America |
01/15/15
20150017197 | Hcv vaccines and methods for using the same
Improved anti-hcv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hcv genotype 1a/1b ns3 and ns4a.
Inovio Pharmaceuticals, Inc. |
01/15/15
20150017193 | Rab6kifl/kif20a epitope peptide and vaccines containing the same
The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of seq id nos: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of seq id nos: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject.
Oncotherapy Science, Inc. |
01/15/15
20150017191 | Adjuvant formulations comprising tlr4 agonists and methods of using the same
Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a tlr4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (hlb) of the emulsion is greater than about 9..
Infectious Disease Research Institute |